A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

April 14, 2023

Primary Completion Date

April 9, 2024

Study Completion Date

August 21, 2024

Conditions

Long COVID

Interventions

DRUG

Nirmatrelvir

Two 150 mg tablets taken by mouth every 12 hours.

DRUG

Ritonavir

One 100 mg capsule taken by mouth every 12 hours.

DRUG

Placebo

Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.

Trial Locations (1)

Yale University, New Haven